Phase I study of ERY-ASP in newly diagnosed Acute-lymphoblastic-leukaemia (ALL)
Phase of Trial: Phase I
Latest Information Update: 11 Sep 2017
At a glance
- Drugs ERY-ASP (Primary)
- Indications Acute lymphoblastic leukaemia
- Focus Therapeutic Use
- 11 Sep 2017 According to an ERYtech Pharma media release, all patients in the third dose escalation cohort of this study have been treated and a decision on the recommended phase 2 dosing is expected in the coming weeks, which will enable the company to begin planning of a pivotal phase 3 study.
- 02 Mar 2017 According to an ERYTECH media release, this trial is expected to reach the recommended phase 2 dose in mid-2017.
- 03 Nov 2016 According to an ERYTECH media release, enrollment in the second cohort has been completed and recommended phase II dose is expected in the first quarter of 2017.